​

Funding Round

Post-IPO Equity - Pardes Biosciences

Post-IPO Equity - Pardes Biosciences

Investment Firm

Overview

Pardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus.

Announced Date

Dec 27, 2021

Funding Type

Post Ipo Equity

Highlights

Location

United States, North America

Social

Investor Lead

Foresite Capital

Foresite Capital

Foresite Capital is a early_stage_venture and late_stage_venture and post_ipo and private_equity and venture firm.

Participant Investors

8

Investor Name
Participant InvestorEcoR1 Capital
Participant InvestorForesite Capital
Participant InvestorT. Rowe Price
Participant InvestorGilead Sciences
Participant InvestorFrazier Healthcare Partners

Round Details and Background

Pardes Biosciences raised $75000000 on 2021-12-27 in Post-IPO Equity

Pardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Feb 03, 2021
Funding Round - Pardes Biosciences
1-51.6M
Dec 27, 2021
Post-IPO Equity - Pardes Biosciences
8-75.0M
Sep 07, 2020
Pre Seed Round - Pardes Biosciences
2-undefined

Recent Activity

There is no recent news or activity for this profile.